Alectinib Offers Hope for Crizotinib-Resistant NSCLC

Alectinib dose has been defined for phase II trial in NSCLC patients after crizotinib failure...

ESMO members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.